Article Sidebar

Submitted
Apr 15, 2021
Published
Apr 15, 2021
Download
PDF
Statistic
Read Counter : 76 Download : 37

Main Article Content

Abstract

Background


Epilepsy is one of the most common neurological disorders worldwide which requires incorporation of complex therapeutic regimens in daily routines. Success of the antiepileptic drugs (AEDs) regimen depends on the medication adherence. Non-adherence leads to recurrence, higher incidence of hospital admissions and imposes economic burden.


Objectives


To assess the factors contributing to self reported drug adherence of AEDs.


Materials and Methods


The study was conducted at the Neurology OPD, BMCRI for 6 months. 200 patients diagnosed with seizure disorder and prescribed AEDs were enrolled. Medication adherence was measured by patient self report using a single item question. The demographic and clinical variables of adherent and non-adherent patients were compared.


Results


Outof the 200 patients, 105 (52.5%) were males, mean age of the patients was 37.87±16.41 years and mean duration of epilepsy was 8.05+7.39 years. Most commonly prescribed AED was Carbamazepine (42%). About 11% of the patients reported adverse drug reactions (ADRs). 64.5% (129) of them were found to be adherent to AEDs and 35.5% (71) were non-adherent. Univariate Analysis showed that Age, education status, marital status, seizure burden, polytherapy and ADRs had a statistically significant association (p=<0.05) with self reported drug adherence. Regression analysis depicted that Marital status and ADRs best predicted non-adherence to AEDs. Conclusion


35.5% of the patients were found to be non-adherent to AEDs. Non adherence was significantly higher among married patients and those who developed ADRs.

Keywords

Epilepsy Antiepileptic drugs Self reported drug adherence Non adherence Adverse drug reactions

Article Details

How to Cite
Dr. Mohammed Yaqub Pasha, Dr.Debdipta Bose, Dr.Sushma M, & Dr.Jagadish B. Agadi. (2021). Assessment of factors influencing self reported drug adherence to anti-epileptic drugs at a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 163-169. https://doi.org/10.61096/ijrpp.v6.iss2.2017.163-169
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Suresh SH, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures. Epilepsy Res Treat. 2015, 1–6.
  2. [2]. Sander JW. The use of antiepileptic drugs--principles and practice. Epilepsia. 45(6), 2004, 28–34.
  3. [3]. Hui ACF, Wong A, Wong HC, Man BL, Au-Yeung KM, Wong KS. Refractory epilepsy in a Chinese population. ClinNeurolNeurosurg. 109(8), 2007, 672–5.
  4. [4]. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J ClinEpidemiol. 54, 2001, 57–60.
  5. [5]. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. ClinTher. 23(8), 2001, 1296–310.
  6. [6]. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav EB. 3(4), 2002, 338–42.
  7. [7]. Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav EB. 14(2), 2009, 372–8.
  8. [8]. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 71(20), 2008, 1572–8.
  9. [9]. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 49(3), 2008, 446–54.
  10. [10]. Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav EB. 13(2), 2008, 316–22.
  11. [11]. Gomes MDM, Maia Filho HDS, Universidade Federal do Rio de Janeiro. Medication-taking behavior and drug self regulation in people with epilepsy. Arq Neuropsiquiatr.56(4), 1998, 714–9
  12. [12]. Wu J-R, DeWalt DA, Baker DW, Schillinger D, Ruo B, Bibbins-Domingo K, et al. A single-item self-report medication adherence question predicts hospitalisation and death in patients with heart failure. J ClinNurs. 23(17-18), 2014, 2554–64.
  13. [13]. Gurumurthy R, Chanda K, Sarma G. An evaluation of factors affecting adherence to anti-epileptic drugs in patients with epilepsy: a cross-sectional study. Singapore Med J. 25, 2016, 325-2
  14. [14]. Nakhutina L, Gonzalez JS, Margolis SA, Spada A, Grant A. Adherence to antiepileptic drugs and beliefs about medication among predominantly ethnic minority patients with epilepsy. Epilepsy Behav EB. 22(3), 2011, 584–6.
  15. [15]. Gabr WM, Shams MEE. Adherence to medication among outpatient adolescents with epilepsy. Saudi Pharm J SPJ OffPubl Saudi Pharm Soc. 23(1), 2015, 33–40.
  16. [16]. Liu J, Liu Z, Ding H, Yang X. Adherence to treatment and influencing factors in a sample of Chinese epilepsy patients. Epileptic DisordInt Epilepsy J Videotape. 15(3), 2013, 289–94.
  17. [17]. Ferrari CMM, de Sousa RMC, Castro LHM. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 22(5), 2013, 384–9.
  18. [18]. Lusić I, Titlić M, Eterović D. [Epileptic patient compliance with prescribed medical treatment]. ActaMedica Croat C̆asopisHravatskeAkad Med Znan. 59(1), 2005, 13–8.
  19. [19]. Cooper JK, Love DW, Raffoul PR. Intentional prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc. 30(5), 1982, 329–33.
  20. [20]. Bautista RED, Rundle-Gonzalez V. Effects of antiepileptic drug characteristics on medication adherence. Epilepsy Behav EB. 23(4), 2012, 437–41.
  21. [21]. Sweileh WM, Ihbesheh MS, Jarar IS, Taha ASA, Sawalha AF, Zyoud SH, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav EB. 21(3), 2011, 301–5.
  22. [22]. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. ActaNeurol Scand. 118(5), 2008, 281–90.
  23. [23]. Uthman BM, Professor and Vice Chair, Department of Neurology, Weill Cornell Medical College in Qatar, Qatar Foundation and Hamad Medical Corporation, Doha, Qatar. Extended-release Antiepilepsy Drugs—Review of the Effects of Once-daily Dosing on Tolerability, Effectiveness, Adherence, Quality of Life, and Patient Preference. US Neurol. 10(01), 2014, 30.
  24. [24]. Martins HH, Alonso NB, Guilhoto LM, Guaranha MS, Yacubian EM. Adherence to treatment in patients with juvenile myoclonic epilepsy: correlation with quality of life and adverse effects of medication. J Epilepsy ClinNeurophysiol 15, 2009, 192-6.
  25. [25]. Stephenson BJ. Is This Patient Taking the Treatment as Prescribed? J Am Med Assoc. 269(21), 1993, 2779.